| abstract |
The present invention relates to a novel canabidiol quinone derivative represented by formula (I): Formula (I) Wherein R is a carbon atom of a linear or branched group, such as an alkyl, aryl, alkenyl, alkynyl, acyl or alkoxycarbonyl group; Or R is a nitrogen atom of a linear or branched group, such as an alkylamine, arylamine, alkenylamine or alkynylamine group. In addition, the present invention uses any compound of formula (I) as a medicament, and in the treatment, particularly to treat diseases and conditions responsive to PPARg modulation due to the high PPARg agonist effect without electrophilic (Nrf2 activation) and cytotoxic activity. It relates to the use for use. In addition, the present invention also provides a pharmaceutical composition containing the compound and a method of treating a disease with the compound. |